Mycobacterium tuberculosis (MTB) is capable of invading not only macrophages (Mφs
Introduction
Multidrug-resistant tuberculosis is currently increasing in the world. [1] [2] [3] In human pulmonary tuberculosis, most tubercle bacilli in the cavity are outside macrophages (Mφs). 4 However, in the external zone of the cavity wall, there is a zone of granulation tissue that is rich in capillaries, Mφs, lymphocytes, granulocytes, etc. and, in this area, Mφs play important roles in the elimination of the pathogens and the prevention of bacterial dissemination to other sites. 4, 5 Participation of host Mφs in the elimination of tubercle bacilli from the infection sites in human tuberculosis has been well demonstrated. [6] [7] [8] Recently, it has been demonstrated that the susceptibility of West Africans to tuberculosis is strongly dependent on the genotypes of the Nramp1 gene, which regulates Mφ antimicrobial function against mycobacterial pathogens including Mycobacterium tuberculosis. 9, 10 This finding indicates that Mφs play key roles in the expression of protective immunity against the M. tuberculosis infection in humans.
In pulmonary M. tuberculosis infections, the cells, which initially encounter the pathogens, are alveolar Mφs and alveolar epithelial cells. 11 By an electron microscopic study on the M. tuberculosis infection in mice, we have demonstrated that the pathogens invaded type II lung pneumocytes during the early phases of the infection. 12 It has also been found that M. tuberculosis internalized and vigorously multiplied within not only Mφs but also type II lung epithelial cells. 11, 13 These findings strongly suggest that the pneumocytes act as sites of bacterial growth in lung infections due to mycobacterial pathogens. We thus compared the antimicrobial activities of new fluoroquinolones, including a C-8-methoxy quinolone gatifloxacin 14 and a C-8-chloro quinolone sitafloxacin, 15 against M. tuberculosis replicating within human Mφs and type II alveolar cells. 
Materials and methods

Organisms
Antimicrobial agents
Gatifloxacin (Kyorin Pharmaceutical Co., Tokyo, Japan), sitafloxacin (Daiichi Pharmaceutical Co., Tokyo, Japan), and levofloxacin (Daiichi Pharmaceutical Co.) were used. The drugs were dissolved in 0.1 N NaOH at 3 mg/mL, and diluted in appropriate culture media before use. The MICs of gatifloxacin, sitafloxacin and levofloxacin measured by the broth microdilution method using 7HSF medium 16 were 0.125, 0.06 and 0.25 mg/L, respectively. The C max values in human blood after oral administration of clinical dosages were as follows: 1.7 mg/L for gatifloxacin (4 mg/kg), 17 1.0 mg/L for sitafloxacin (2 mg/L), 18 and 2.0 mg/L for levofloxacin (4 mg/kg) (personal communication from Dr K. Namba, Daiichi Pharmaceutical Co.).
Cell lines
Mono Mac 6 human monocytic cell line (MM6-Mφs) and A-549 human type II alveolar epithelial cell line (A-549 cells) were obtained from the German Collection of Microorganisms and Cell Cultures (Mascheroder, Braunschweig, Germany) and the American Type Culture Collection (Rockville, MD, USA), respectively. MM6-Mφs were subcultured in RPMI 1640 medium (Nissui Pharmaceutical Co., Tokyo, Japan) supplemented with 10% (v/v) fetal bovine serum (FBS; Bio Whittaker Co., Walkersville, MD, USA), 1% (v/v) nonessential amino acids (Bio Whittaker), 1 mM sodium pyruvate (Bio Whittaker) and 9 mg/L bovine insulin (Wako Pure Chemical Industries, Osaka, Japan). A-549 cells were subcultured in Ham's F-12K medium (Dainippon Pharmaceutical Co., Osaka, Japan) supplemented with 10% FBS.
Antimicrobial activity against intracellular organisms
The antimicrobial activities of test drugs against organisms replicating within MM6-Mφs and A-549 cells were measured as follows. 
MM6-Mφs
Uptake of quinolones by MM6-Mφs and A-549 cells
MM6-Mφs and A-549 cells (2 × 10 6 cells) were cultured in 10 mL of culture medium (MM6-Mφs: 5% FBS-RPMI 1640 medium; A-549 cells: 5% FBS-Ham's F-12K medium) in plastic culture plates (90 mm diameter) in the presence of 100 mg/L of test quinolones at 37°C for 24 h. After rinsing the cultured cells with PBS, cells were collected by centrifugation (800g, 5 min), suspended in 100 µL of distilled water, and gently sonicated in a sonicator bath at 37°C for 2 h. The resultant cell lysate was mixed with 5 volumes of TS broth and the resultant solution (50 µL each) was then subjected to serial two-fold dilution with TS broth in microculture wells (96 wells: U-bottom: Becton Dickinson). To each well containing drug dilutions was added 10 µL of TS broth containing 5 × 10 3 cfu of S. aureus, thereafter cultured at 37°C for 24 h, and observed for the maximal dilution that caused growth inhibition of S. aureus ('growth inhibition titre'). For calibration of the concentrations of quinolones in test cell lysates, standard serial two-fold dilutions of test quinolones were also determined for their 'growth inhibition titre'.
Statistical analysis
Statistical analysis was carried out by Student's t-test.
Results
Activities of test quinolones against intramacrophage M. tuberculosis
We examined the antimicrobial activities of gatifloxacin, sitafloxacin and levofloxacin at the MIC and C max against M. tuberculosis residing within MM6-Mφs. As shown in Figure 1 (a), sitafloxacin and gati- floxacin added at the MIC caused growth inhibition of intramacrophage M. tuberculosis, and levofloxacin caused growth inhibition of the organisms at day 3. The efficacy was in the order of sitafloxacin > gatifloxacin > levofloxacin. Notably, complete inhibition of bacterial growth was noted for sitafloxacin. On the other hand, the test quinolones exhibited bactericidal activity against intramacrophage M. tuberculosis when added at the C max [ Figure 1(b) ]. The efficacy was in the order of gatifloxacin > levofloxacin ≥ sitafloxacin, in terms of the rate of bacterial elimination during 3-and 5-day cultivation of infected Mφs due to drugs. As shown in Table 1 , when the test drugs were added at lower concentrations (1/8C max to 1/2C max ) and the bactericidal activities of drugs were determined in terms of bacterial elimination during 7-day cultivation, the efficacy was in the order of sitafloxacin > gatifloxacin > levofloxacin. In this experiment, sitafloxacin added at the C max exerted the same level of bactericidal activity as gatifloxacin.
Activities of test quinolones against M. tuberculosis within A-549 cells
Next, we examined the antimicrobial activities of test quinolones against M. tuberculosis residing inside A-549 cells. As shown in Figure 2(a) , when the test quinolones were added at the MIC, sitafloxacin and gatifloxacin but not levofloxacin caused growth inhibition of M. tuberculosis inside the A-549 cells. The efficacy was in the order of sitafloxacin ≥ gatifloxacin > levofloxacin. On the other hand, the test quinolones more or less exhibited bactericidal activity against the organisms residing in A-549 cells, when added at the C max [ Figure  2(b) ]. The efficacy was in the order of gatifloxacin > sitafloxacin > levofloxacin, in terms of the rate of bacterial elimination during 3-and 5-day cultivation of infected Mφs due to drugs. As shown in Table 2 , when the test drugs were added at lower concentrations (1/8C max to 1/2C max ) and the bactericidal activities of drugs were determined in terms of bacterial elimination during 7-day cultivation, the efficacy was in the order of sitafloxacin > gatifloxacin > levofloxacin. In this experiment, both sitafloxacin and gatifloxacin when added at C max caused complete elimination of intracellular M. tuberculosis. Table 3 shows the profiles of the intracellular accumulation of test quinolones in MM6-Mφs and A-549 cells. First, the efficacies of the drug uptake by these cells were in the order of sitafloxacin > gatifloxacin > levofloxacin. Next, there was no significant difference in the uptake of individual quinolones between MM6-Mφs and A-549 cells, although a tendency was noted that MM6-Mφs showed a somewhat greater accumulation of sitafloxacin and levofloxacin than did the A-549 cells. In this context, it appears that the profiles of intracellular drug accumulation may be dependent on the media used for cultivation of individual cells (RPMI 1640 and Ham's F-12K medium for MM6-Mφs and A-549 cells, respectively), since variation in composition of culture media can influence the antibiotic intracellular equilibrium in these cells. Since this experiment was carried out using drugs at a non-physiological concentration (100 mg/L), it is possible that such a high concentration of test drugs might reduce the viability of test cells. Our separate experiments, using nigrosin exclusion testing, indicated that the percentage of viable cells did not reduce even after 24-h cultivation of MM6-Mφs and A-549 cells in the medium containing 100 mg/L of test drugs, as follows: (1) MM6-Mφs: control (-drug), 98.5%; +gatifloxacin, 98.0%; +sita-floxacin, 98.5%; +levofloxacin, 98.5%: (2) A-549 cells: control (-drug), 99.9%; +gatifloxacin, 99.9%;+sitafloxacin, 99.9%; +levofloxacin, 99.9%. Therefore, it is thought that the concentrations of drugs used in this experiment (100 mg/L) were not cytotoxic to these cells. 
Uptake of test quinolones by MM6-Mφs and A-549 cells
Discussion
This study indicated the following. First, when gatifloxacin, sitafloxacin and levofloxacin were added at the MIC to the culture medium of MM6-Mφs or A-549 cells infected with M. tuberculosis, the antimicrobial activities of these quinolones against intracellular M. tuberculosis were substantially dependent on their activity against extracellular M. tuberculosis based on the MIC values, in the order of sitafloxacin, gatifloxacin and levofloxacin. Second, when these quinolones were added to the culture medium at the C max , such a relationship was not observed. Although both quinolones exerted bactericidal effects against the intracellular organisms, gatifloxacin exhibited much more potent activity against M. tuberculosis residing inside MM6-Mφs or A-549 cells compared to sitafloxacin, when the activity of drugs was determined in terms of the rate of drug-mediated bacterial elimination during 3-and 5-day cultivation of infected cells. Notably, when drugs were added to the culture medium of test cells at the 1/8C max to 1/2C max and the bactericidal activities of drugs were determined in terms of bacterial elimination during 7-day cultivation, the efficacy was in the order of sitafloxacin > gatifloxacin > levofloxacin.
Third, the efficacies of intracellular uptake of these quinolones by MM6-Mφs and A-549 cells were both markedly different from quinolone to quinolone, in the order of sitafloxacin > gatifloxacin > levofloxacin. This indicates that sitafloxacin has superior pharmacological characteristics in terms of intracellular uptake and accumulation by lung cells including Mφs and alveolar epithelial cells. However, the possibility cannot be excluded that the observed profiles of Mφ uptake of quinolone are limited to the case of MM6-Mφs, since it has been observed that the efficacies of the uptake of levofloxacin and sitafloxacin by THP-1 human Mφ cell line did not markedly differ from each other (personal communication from Dr K. Namba, Daiichi Pharmaceutical Co.).
It is enigmatic to note that profiles of the antimicrobial activity expression of the test quinolones, especially sitafloxacin, against intracellular M. tuberculosis significantly changed depending on the concentration of the drugs which were added to the culture medium. For instance, although sitafloxacin exhibited the most potent activity against M. tuberculosis inside MM6-Mφs and A-549 cells when added at the MIC or 1/8C max to 1/2 C max concentrations, its activity was significantly less than gatifloxacin when added at higher concentration such as C max . This situation may be simply explained by the recent finding of Paillard et al. 19 that the ratio of the cellular to extracellular concentration of a certain quinolone (moxifloxacin) is different in infected and uninfected cells (THP-1 Mφs). Indeed, in this study, we examined profiles of the drug accumulation using uninfected cells. Alternatively, it is also possible that the mode of intracellular accumulation of the test quinolones may differ depending on the concentration at which the drugs were added to the culture medium of MM6-Mφs or A-549 cells infected with M. tuberculosis.
In any case, the present findings may indicate that the MIC values of fluoroquinolones are not always predictive of their antimicrobial activity against intracellular M. tuberculosis replicating within Mφs and type II pneumocytes. Since, in the early phases of M. tuberculosis infection in the lungs, the majority of infected tubercle bacilli are replicating within alveolar Mφs, interstitial Mφs, or type II alveolar epithelial cells, 12, 20 this result means that the MIC values of quinolones are not sufficiently predictive of their therapeutic effects against tuberculosis especially in the early stage. This may also be the case in disseminated tuberculosis in which most M. tuberculosis organisms are residing within Mφs. In addition, this study indicated that a C-8-methoxy quinolone, gatifloxacin, exhibited strong microbicidal activity against intracellular M. tuberculosis regardless of the host cells, such as Mφs and type II pneumocytes, when added at the C max in the blood. It is reported that the concentration of gatifloxacin in the lungs of rats given an oral administration of the drug was higher than its serum concentration (4.58 mg/L in the lungs versus 2.60 mg/L in the blood 1 h after a single oral administration of gati- Table 3 . Uptake of gatifloxacin, sitafloxacin and levofloxacin by MM6-Mφs and A-549 cells a a Test cells (2 × 10 6 ) were incubated in 10 mL of culture medium in the presence of 100 mg/L each of test quinolones at 37°C for 24 h, and the amount of intracellularly accumulated drug was measured as described in the text. floxacin at a dose of 10 mg/kg). 21 It thus appears that this quinolone may exert good therapeutic effects in treating patients during the early phases of pulmonary tuberculosis.
